Myasthenia Gravis
Myasthenia gravis is a chronic autoimmune condition in which the immune system attacks the junction between nerves and muscles. The result is muscle weakness that tends to worsen during activity and improve with rest. It is uncommon, though it may be slightly more prevalent in younger women, according to registry data.
Key points
- The immune system mistakenly targets the connection between nerve and muscle, blunting the signal that tells muscle fibres to contract.
- Weakness fluctuates through the day, easing with rest and increasing with exertion, and the condition appears to affect younger women somewhat more often.
- Cholinesterase inhibitors help acetylcholine linger at the junction to restore transmission, while immune-suppressing therapy addresses the disease’s underlying cause long term.
How myasthenia gravis is managed
The condition does not yet have a cure, but symptoms can be controlled effectively. The mainstay of symptomatic treatment is pyridostigmine, a cholinesterase inhibitor that allows acetylcholine to accumulate at the nerve-muscle junction, improving signal transmission. Longer-term management typically also involves immunosuppression to reduce the underlying autoimmune attack. A neurology specialist usually oversees care, adjusting therapy as symptoms fluctuate. Anyone experiencing sudden severe weakness, difficulty swallowing, or breathing difficulty should seek emergency care immediately, as these can signal a myasthenic crisis.